Research News

Immunotherapy as treatment for gastric or esophageal adenocarcinoma (GEAC)

Summary

The combination of chemotherapy (or targeted therapy) with immunotherapy is emerging rapidly as a promising strategy in the first line treatment against several tumor types. This study led by Dr Raghav Sundar provides the basis to further optimise treatment options for first-line metastatic GEAC patients using combination of Immunotherapy and chemotherapy.

 

Link to article: https://bit.ly/35WzvHy

 

Share this story:
Facebook
Twitter
LinkedIn

Related Research News

Giving

Recharging the Aging Brain: DMTF1 to the Rescue

As we age, stem cells in the brain — responsible for repair and renewal—become less active. Researchers, led by N2CR …

Read More →
Giving

New Book by Prof Goh Boon Cher & A/Prof Wang Lingzhi

We are pleased to share that Prof. Goh Boon Cher and A/Prof. Wang Lingzhi have published a new edited volume …

Read More →
Giving

New Hope for Treating Drug-Resistant Leukaemia

Acute myeloid leukaemia (AML) is a fast-growing blood cancer that often becomes resistant to standard treatments. This resistance is linked …

Read More →